MAbSilico

MAbSilico

Biotechnologie

The only TechBio providing computationally designed antibodies through AI with biological validations associated

À propos

MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery. We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies. While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation. Using NLP technologies we gather information about antibodies and their target in different databases to ensure competitive landscape analysis and the freedom to operate of the computationally designed antibodies candidates.

Secteur
Biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Tours
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2017
Domaines
Biotechnology, Therapeutic antibody, Antibody, Protein interaction, Epitope mapping, AI, Computation, HPC , in silico, Antibody design et Protein design

Lieux

Employés chez MAbSilico

Nouvelles

Pages similaires

Parcourir les offres d’emploi